Skip to main content
Clinical Trials/DRKS00029595
DRKS00029595
Recruiting
未知

kontina(R) for the self-management of patients with overactive bladder - PEK-OAB

APOGEPHA Arzneimittel GmbH0 sites208 target enrollmentOctober 13, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
N32.8
Sponsor
APOGEPHA Arzneimittel GmbH
Enrollment
208
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 13, 2022
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\) Male and female subjects aged at least 18 years
  • 2\) Subjects with OAB
  • \- with or without urgency urinary incontinence (UUI) OR
  • \- with or without mixed urinary incontinence (MUI) for which the investigator determines that UUI is predominant to the subject
  • 3\) Subjects with a history of symptoms of OAB (at least three months) who are treatment\-naïve or stopped prior OAB treatment at least four weeks ago and for whom behavioral therapy, lifestyle interventions or physiotherapy measures are indicated
  • 4\) At least eight micturitions in 24 hrs
  • 5\) BMI from 18 to less than 40 kg/m2
  • 6\) Subjects who have access to a mobile device and are skilled in the use of it
  • 7\) Subjects who are able to understand, read and write German
  • 8\) Willing and capable of providing informed consent to use kontina® and participate in all assessments associated with the clinical study

Exclusion Criteria

  • 1\) Use of other PFMT app or bladder training app
  • 2\) Red\-flag symptoms and genitourinary conditions:
  • \- Stress urinary incontinence
  • \- Painful urgency
  • \- Acute or Recurrent urinary tract infections (2 UTIs in the last 6 months or \= 3 UTIs in the last 12 months)
  • \- Macroscopic or microscopic haematuria
  • \- Non\-investigated bladder emptying difficulties
  • \- Suspicion of or known anomalies of the lower urinary tract (according to assessment by or in the opinion of the investigator)
  • \- Suspicion of or known cancer in bladder or pelvic area (according to assessment by or in the opinion of the investigator)
  • \- Intermittent catheterization

Outcomes

Primary Outcomes

Not specified

Similar Trials